China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its next-generation epidermal growth factor receptor (EGFR) inhibitor sunvozertinib (DZD9008). The drug is in late-stage global studies for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (Exon20ins) mutation, both in the second-line stage following chemotherapy and as a first-line therapy.
Study Results
Dizal presented data for the drug in the second-line setting in 119 patients. As of April 30, 2022, the best overall response rate (ORR) was 52.4%, while in patients with baseline brain metastasis, the best ORR reached 44%. The drug also demonstrated a safety profile “amenable to long-term treatment,” with the most common drug-related treatment-emergent adverse events being diarrhea and rash, the majority of which were Grade 1 and 2.
Implications
Dizal views the data, presented at this year’s World Conference on Lung Cancer (WCLC), as indicative of sunvozertinib’s potential best-in-class status. According to a recent study, Exon20ins mutations account for 4%-12% of all EGFR mutations in NSCLC. However, this tumor type is not responsive to other EGFR treatments, and currently, affected patients have no satisfactory therapeutic options available.-Fineline Info & Tech
